Retinoic Acid, Arsenic Trioxide Combined With Low Dose Homoharringtonine Alkali Treatment Of Acute Promyelocytic Leukemia Clinical Analysis

Objective To study the feasibility,effectiveness and adverse reaction of ATRA,ATO combined with low dose HHT in treating acute promyelocytic leukemia.Methods To choose 24 first-visit patients with APL who were divided into research group and control group randomly. The research group were accepted induced therapy with ATRA,ATO and low dose HHT, consolidation therapy with two HA programs; while the control group were accepted induced therapy with ATRA,ATO and DNR, consolidation therapy with two DA programs. To analyse the CR rate,PML/RARa fusion gene negative conversion rate and adverse reactions of these two groups at the time when they ended induced therapy and consolidation therapy seperately.Results After induced therapy, the research group accepted haematological remission completely and PML/RARa fusion gene turned negative in 69.2% of them, while the control group all accepted haematological remission except one patient died in the egg and PML/RARa fusion gene turned negative in 60% of them. After consolidation therapy, PML/RARa fusion gene all turned negative in the research group and 90% in the control group. Among induced therapy, patients in these two groups seperately accepted blood plasma infusion were 970ml vs 1100ml, platelet infusion were 28u vs 67u,and the incidence of sepsis were 7.69% vs 40%, the in-patient costs were 19314 RMB vs 29335 RMB on average. The curative effect,PML/RARa fusion gene negative conversion rate and the adverse reaction were similar between these two groups. While the research group can bring lower platelet infusion incidence of sepsis and thereupon lower costs.Conclusion As a new choice of treating new-diagonised APL, ATRA,ATO combined with low dose HHT can also achieve molecular remission, and bring lower complications and therapy costs.So this program make.the rate of quitting threrapy decreased and prognosis improved obviously.